Incidence and causes of hospitalization in patients with transthyretin (ATTR-CA) and light chain (AL-CA) cardiac amyloidosis

被引:0
|
作者
Enriquez-Vazquez, Daniel [1 ,2 ]
Gomez-Martin, Carlos [3 ]
Barge-Caballero, Gonzalo [1 ,2 ]
Barge-Caballero, Eduardo [1 ,2 ]
Lopez-Perez, Manuel [4 ]
Bilbao-Quesada, Raquel [5 ]
Gonzalez-Babarro, Eva [6 ]
Gomez-Otero, Ines [2 ,7 ]
Lopez-Lopez, Andrea [8 ]
Gutierrez-Feijoo, Mario [9 ]
Varela-Roman, Alfonso [2 ,7 ]
Crespo-Leiro, Maria G. [1 ,2 ]
机构
[1] Complexo Hosp Univ Coruna CHUAC, Serv Cardiol, Unidad Insuficiencia Cardiaca Avanzada & Trasplant, La Coruna, Spain
[2] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Cardiovasc CIBE, Madrid, Spain
[3] Hosp Univ Virgen de las Nieves, Granada, Spain
[4] Complexo Hosp Univ Ferrol CHUF, Serv Cardiol, La Coruna, Spain
[5] Complexo Hosp Univ Vigo CHUVI, Serv Cardiol, Vigo, Pontevedra, Spain
[6] Complexo Hosp Pontevedra CHOP, Serv Cardiol, Pontevedra, Spain
[7] Complexo Hosp Univ Santiago de Compostela CHUS l S, Serv Cardiol, La Coruna, Spain
[8] Hosp Univ Lucus Augusti HULA, Serv Cardiol, Lugo, Spain
[9] Complexo Hosp Univ Ourense CHUOU, Serv Cardiol, Orense, Spain
来源
MEDICINA CLINICA | 2024年 / 162卷 / 07期
关键词
Cardiac amyloidosis; Transthyretin amyloidosis; Light chain amyloidosis; Hospitalizations; Hospital admissions; Heart failure; DIAGNOSIS;
D O I
10.1016/j.medcli.2024.01.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction and objetives: Cardiac amyloidosis (CA) is a disorder associated with high number of hospital admissions. Given the scarce information available, we propose an analysis of the incidence and causes of hospitalization in this disease. Material and methods: One hundred and forty-three patients [128 by transthyretin (ATTR-CA) and 15 by light chains (AL-CA)] included in Registro de Amiloidosis Cardiaca de Galicia (AMIGAL) were evaluated, including all hospitalizations. Results: During a median follow-up of 959 days there were 179 unscheduled hospitalizations [incidence rate (IR) 512.6 admissions per 1000 patients-year], most common due to cardiovascular reasons (n = 109, IR 312.2). Most frequent individual cause of hospitalization was heart failure (n = 87, TI 249.2). AL-CA was associated with a higher IR of unscheduled hospitalizations than ATTR-CA (IR 781 vs. 483.2; HR 1.62; p = 0,029) due to non-cardiovascular admissions (IR 376 vs. 181.2; HR 2.07; p = 0.027). Unscheduled admission-free survival at 1 and 3 years in AL-CA was inferior than in ATTR-CA (46.7% and 20.0% vs. 73.4% and 35.2%, respectively; p = 0.021). Conclusions: CA was associated with high incidence of hospitalizations, being heart failure the most frequent individual cause; unscheduled admission-free survival in AL-CA was lower than in ATTR-CA due mostly to non-cardiovascular admissions. (c) 2024 Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:e1 / e7
页数:7
相关论文
共 50 条
  • [1] Right ventricular longitudinal strain in transthyretin cardiac amyloidosis (ATTR-CA)
    Accietto, A.
    Saturi, G.
    Caponetti, A. G.
    Giovannetti, A.
    Ponziani, A.
    Ruotolo, I.
    Cecchieri, F.
    Laurenzano, F.
    Gagliardi, C.
    Sguazzotti, M.
    Massa, P.
    Biagini, E.
    Galie', N.
    Longhi, S.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [2] The role of Nuclear Medicine studies in the evaluation of transthyretin cardiac amyloidosis (ATTR-CA).
    Koutsikos, John
    Giourgouli, Stamatia
    Velidaki, Antigoni
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [3] Role of age and QRS duration as mortality predictors in a cohort of patients with transthyretin cardiac amyloidosis (ATTR-CA)
    Espinoza Romero, Cristhian Vicente
    Bueno, Bruno
    Pereira, Natalia Melo
    Luzuriaga, Georgina Jadan
    Fernandes, Fabio
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2024, 31 : S23 - S23
  • [4] Prevalence of transthyretin cardiac amyloidosis (ATTR-CA) in a population of patients with hip and knee arthroplasty: could they be early signs?
    Paccagnella, A.
    Bonfiglioli, R.
    Mattana, F.
    Mei, R.
    Saturi, G.
    Massa, P.
    Caponetti, G.
    Sguazzotti, M.
    Ponziani, A.
    Gagliardi, C.
    Longhi, S.
    Galie, N.
    Fanti, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S528 - S528
  • [5] Differential progression of cardiac structure and function in transthyretin cardiac amyloidosis (ATTR-CA) following treatment with tafamidis and diflunisal
    Scharf, Rebecca
    Schmidt, Alexander
    Ullah, Ikram
    Gopal, Deepa
    Siddiqi, Omar
    Ruberg, Frederick
    CIRCULATION, 2024, 150
  • [6] Efficacy and safety of diflunisal therapy in patients with transthyretin cardiac amyloidosis (ATTR-CA): a systematic review and meta-analysis
    Huang, Wilbert
    Frederich, Alvin
    Nurhafizah, Apridya
    Salma, Antania Devita
    Zahrani, Rivera Adenia Firza
    Retnoningrum, Intan Aulia
    EGYPTIAN HEART JOURNAL, 2025, 77 (01):
  • [7] Voltage/mass ratio (VMR) prognosis value in heart failure (HF) patients with transthyretin cardiac amyloidosis (ATTR-CA)
    Costa, J.
    Pierre, M.
    Nazeyrollas, P.
    EUROPEAN HEART JOURNAL, 2023, 44 : 46 - 46
  • [8] VARIABILITY IN ESTIMATED GLOMERULAR FILTRATION RATE WITH CYSTATIN C VS CREATININE IN PATIENTS WITH TRANSTHYRETIN CARDIAC AMYLOIDOSIS (ATTR-CA)
    Chung, Alice
    Driggin, Elissa
    Clerkin, Kevin J.
    Teruya, Sergio Luis
    Santos, Jeffeny De Los
    Maurer, Mathew S.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 619 - 619
  • [9] Transthyretin cardiac amyloidosis (ATTR-CA) by Cardiac Scintigraphy with 99mTc-diphosphonates (CS) and Cardiovascular Magnetic Resonance Imaging (CMRI)
    Pudis, M.
    Bondia-Bescos, S.
    Hervas-Sanz, B.
    Notta, P. C.
    Rodriguez, I. E. Sanchez
    Palomar-Munoz, A.
    Yun, S.
    Diez-Lopez, C.
    Claver-Garrido, E.
    Buaki-Sogo, M.
    Gracia-Sanchez, L. M.
    Cortes-Romera, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S540 - S541
  • [10] PULMONARY INVOLVEMENT IN SYSTEMIC LIGHT CHAIN (AL) AND TRANSTHYRETIN (ATTR) AMYLOIDOSIS
    Smith, E.
    Strachan, L.
    Gibbs, S.
    RESPIROLOGY, 2021, 26 : 20 - 20